Novartis Avidity Drug Fails in Third Trial Setback in a Week
Product·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novartis suffered its third clinical-trial setback in a week after del-desiran, a treatment for a rare muscle-wasting disease, failed a late-stage study.
This failure adds to the challenges faced by Novartis as it seeks to advance its drug development pipeline amid increasing scrutiny.
Novartis
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Novartis suffered its third clinical-trial setback in a week after del-desiran, a treatment for a rare muscle-wasting disease, failed a late-stage study.”
Bloomberg — Novartis Avidity Drug Fails in Third Trial Setback in a Week